Ulrica Wilderäng

Also affiliated with UCL Biomedical Research Centre, AstraZeneca (Sweden), University College London

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial”.

Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial

Circulation(2022)10.1161/circulationaha.122.061754

N/A

4.2DataRank · unranked

152 citations

Pardeep S. Jhund, Jan Bělohlávek, Rudolf A. de Boer, Chern‐En Chiang, Akshay S. Desai +22 more

Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan

European Journal of Heart Failure(2022)10.1002/ejhf.2722

N/A

0DataRank · unranked

34 citations

Jawad H. Butt, Toru Kondo, Karola Jering, Kieran F. Docherty, Pardeep S. Jhund +16 more